^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Small Cell Lung Cancer
    Drug:irinotecan (Topoisomerase I inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    SCLC subsequent systemic therapy: Other recommended regimens…Irinotecan
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    …the cisplatin or carboplatin plus Irinotecan regimens are included as options in the NCCN Guidelines for patients with extensive-stage disease…
    Secondary therapy:
    cisplatin; carboplatin